Research and reports in urology · 2026
Psychometric Validation of the QLQ-NMIBC24 in Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Peyton Charles C, Dhanda Rahul, Burke Tom, Tsurutis Victoria, Ugwuoke Nikky, Nadkarni Anagha, Burger Brent, Lee Veronica, Louie Michael J, Stover Angela M
Аннотация
PURPOSE: This study aimed to evaluate the psychometric properties of the EORTC QLQ-NMIBC24 and to propose distribution-based minimal clinically important difference (MCID) thresholds in patients with low-grade, intermediate-risk NMIBC (LG-IR-NMIBC).
PATIENTS AND METHODS: Patients with LG-IR-NMIBC from two phase 3 trials (ATLAS, n = 270; ENVISION, n = 240) completed the EORTC QLQ-C30 (ENVISION only) and QLQ-NMIBC24 questionnaires at baseline, Week 6, and Month 3. Psychometric evaluation of the QLQ-NMIBC24 in the LG-IR-NMIBC population included internal consistency, item convergence, known-groups validity, test-retest reliability and responsiveness to clinical change.
RESULTS: Item-item (0.40-0.96) and item-scale correlations (0.44-0.96) indicated good convergent validity across most domains. Internal consistency was acceptable for all multi-item domains (Cronbach's α 0.78-0.93) except Malaise, which showed lower reliability (Cronbach's α 0.34-0.67). Known-groups comparisons supported the instrument's ability to distinguish patients by physical function (effect sizes up to 1.63) and sex-related domains. Test-retest reliability was generally good for Urinary Symptoms and Sexual Function (ICC 0.79-0.82). Selected domains (Urinary Symptoms, Sexual Intimacy, Malaise) demonstrated responsiveness to clinical change. Distribution-based MCID estimates varied across domains (4.37-16.29), providing potential thresholds for meaningful changes in HRQoL scores. Anchor-based analyses using QLQ-C30 change scores were explored, but correlations with QLQ-NMIBC24 domains (r = -0.37 to 0.01) did not meet the minimum threshold (0.37).
CONCLUSION: The QLQ-NMIBC24 demonstrates valid, reliable, and interpretable measurement properties in patients with LG-IR-NMIBC. Although sensitivity varied across domains, the findings support its use in clinical trials and potentially routine practice. Distribution-based MCID thresholds provide guidance for interpreting meaningful HRQoL changes, though further studies using anchor-based methods are warranted.
PATIENTS AND METHODS: Patients with LG-IR-NMIBC from two phase 3 trials (ATLAS, n = 270; ENVISION, n = 240) completed the EORTC QLQ-C30 (ENVISION only) and QLQ-NMIBC24 questionnaires at baseline, Week 6, and Month 3. Psychometric evaluation of the QLQ-NMIBC24 in the LG-IR-NMIBC population included internal consistency, item convergence, known-groups validity, test-retest reliability and responsiveness to clinical change.
RESULTS: Item-item (0.40-0.96) and item-scale correlations (0.44-0.96) indicated good convergent validity across most domains. Internal consistency was acceptable for all multi-item domains (Cronbach's α 0.78-0.93) except Malaise, which showed lower reliability (Cronbach's α 0.34-0.67). Known-groups comparisons supported the instrument's ability to distinguish patients by physical function (effect sizes up to 1.63) and sex-related domains. Test-retest reliability was generally good for Urinary Symptoms and Sexual Function (ICC 0.79-0.82). Selected domains (Urinary Symptoms, Sexual Intimacy, Malaise) demonstrated responsiveness to clinical change. Distribution-based MCID estimates varied across domains (4.37-16.29), providing potential thresholds for meaningful changes in HRQoL scores. Anchor-based analyses using QLQ-C30 change scores were explored, but correlations with QLQ-NMIBC24 domains (r = -0.37 to 0.01) did not meet the minimum threshold (0.37).
CONCLUSION: The QLQ-NMIBC24 demonstrates valid, reliable, and interpretable measurement properties in patients with LG-IR-NMIBC. Although sensitivity varied across domains, the findings support its use in clinical trials and potentially routine practice. Distribution-based MCID thresholds provide guidance for interpreting meaningful HRQoL changes, though further studies using anchor-based methods are warranted.